| Indicators | Browse All

Annexon, Inc. (ANNX)

Healthcare | Biotechnology | Brisbane, United States | NasdaqGS
4.97 USD -0.28 (-5.333%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 5.01 +0.04 (0.805%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT)

Short-term:★★☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 5:54 a.m. EDT

The investment case here is fundamentally broken. The company is hemorrhaging cash with negative free cash flow and operating cash flow, while returning negative returns on both assets and equity. The balance sheet shows significant debt relative to equity, and the stock has suffered a catastrophic 90% decline over the last five years. Although analysts project a massive upside based on potential trial success, the current reality is a deep value trap where the market has already priced in severe distress. The recent price action shows a slight bounce off lows, but the heavy options positioning suggests smart money is betting against further drops. Without a confirmed catalyst turning the corner on profitability, this remains a speculative gamble rather than an investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.061551
AutoTheta0.062060
AutoETS0.062176
AutoARIMA0.062178

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 40%
H-stat 0.35
Ljung-Box p 0.000
Jarque-Bera p 0.926
Excess Kurtosis -0.06
Attribute Value
Sector Healthcare
Debt to Equity Ratio 13.249
Market Cap 942,208,256
Forward P/E -4.58
Beta 1.22
Website https://www.annexonbio.com

As of Aug. 22, 2026, 5:54 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $3.00 and $4.00) compared to calls. While there is some call volume at higher strikes ($7.00-$10.00), the overwhelming capital deployment is in put writing and buying, suggesting a consensus expectation of continued volatility and potential further declines rather than a breakout.


Info Dump

Attribute Value
52 Week Change 1.536232
Address1 1,400 Sierra Point Parkway
Address2 Building C Suite 200
All Time High 38.01
All Time Low 1.285
Ask 6.46
Ask Size 2
Audit Risk 7
Average Analyst Rating 1.6 - Buy
Average Daily Volume10 Day 2,707,680
Average Daily Volume3 Month 3,618,343
Average Volume 3,618,343
Average Volume10Days 2,707,680
Beta 1.223
Bid 5.0
Bid Size 1
Board Risk 9
Book Value 1.066
City Brisbane
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 4.97
Current Ratio 5.529
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 5.205
Day Low 4.95
Debt To Equity 13.249
Display Name Annexon
Earnings Timestamp 1,786,537,800
Earnings Timestamp End 1,794,227,400
Earnings Timestamp Start 1,794,227,400
Ebitda -208,388,000
Ebitda Margins 0.0
Enterprise To Ebitda -3.89
Enterprise Value 810,698,432
Eps Current Year -1.05
Eps Forward -1.08499
Eps Trailing Twelve Months -1.07
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 650 636 9773
Fifty Day Average 5.4011
Fifty Day Average Change -0.43110037
Fifty Day Average Change Percent -0.07981714
Fifty Two Week Change Percent 153.6232
Fifty Two Week High 7.18
Fifty Two Week High Change -2.21
Fifty Two Week High Change Percent -0.30779946
Fifty Two Week Low 2.03
Fifty Two Week Low Change 2.9399998
Fifty Two Week Low Change Percent 1.4482758
Fifty Two Week Range 2.03 - 7.18
Financial Currency USD
First Trade Date Milliseconds 1,595,597,400,000
Float Shares 163,794,476
Forward Eps -1.08499
Forward P E -4.580687
Free Cashflow -115,986,496
Full Exchange Name NasdaqGS
Full Time Employees 92
Fullday Change -0.28
Fullday Change Percent -5.33334
Fullday Price 5.01
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.00424
Held Percent Institutions 1.02564
Implied Shares Outstanding 189,579,134
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Long Name Annexon, Inc.
Market us_market
Market Cap 942,208,256
Market State CLOSED
Max Age 86,400
Message Board Id finmb_279883519
Most Recent Quarter 1,782,777,600
Net Income To Common -202,668,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 995,290,453
Number Of Analyst Opinions 7
Open 5.18
Operating Cashflow -193,032,992
Operating Margins 0.0
Overall Risk 9
Payout Ratio 0.0
Phone 650 822 5500
Post Market Change 0.04000044
Post Market Change Percent 0.8048378
Post Market Price 5.01
Post Market Time 1,787,959,805
Previous Close 5.25
Price Eps Current Year -4.733333
Price Hint 4
Price To Book 4.6622887
Profit Margins 0.0
Quick Ratio 5.437
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 1.6
Region US
Regular Market Change -0.28
Regular Market Change Percent -5.33334
Regular Market Day High 5.205
Regular Market Day Low 4.95
Regular Market Day Range 4.95 - 5.205
Regular Market Open 5.18
Regular Market Previous Close 5.25
Regular Market Price 4.97
Regular Market Time 1,787,947,201
Regular Market Volume 1,617,732
Return On Assets -0.51542
Return On Equity -1.05261
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 189,579,134
Shares Percent Shares Out 0.1719
Shares Short 32,583,299
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 29,827,889
Short Name Annexon, Inc.
Short Percent Of Float 0.18190001
Short Ratio 10.39
Source Interval 15
State CA
Symbol ANNX
Target High Price 27.0
Target Low Price 7.0
Target Mean Price 14.71429
Target Median Price 12.0
Total Cash 209,243,008
Total Cash Per Share 1.104
Total Debt 24,651,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.07
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.3301
Two Hundred Day Average Change -0.36010027
Two Hundred Day Average Change Percent -0.06755976
Type Disp Equity
Volume 1,617,732
Website https://www.annexonbio.com
Zip 94,005